Pemetrexed in Patients With Advanced Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

March 31, 2010

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Pemetrexed

Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.

Trial Locations (1)

02115

Dana-Farber Cancer Center, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00424723 - Pemetrexed in Patients With Advanced Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter